FDA Updates Authorized Generics Listing, Flagging Data Gaps NDA Sponsors Must Verify

The FDA's updated Authorized Generics listing, published July 2, 2026, carries a direct compliance implication for NDA sponsors and generic manufacturers: the data underpinning market-entry timelines is self-reported, manually compiled, and explicitly unverified by the agency, meaning portfolio decisions or regulatory submissions that rely on this list without independent corroboration carry measurable risk.

The listing is drawn from annual reports submitted to CDER by NDA sponsors since January 1, 1999. Because those reports rarely specify the exact date an authorized generic entered the market, the column labeled "Date Authorized Generic Entered Market" reflects only the reporting period in which the product was first disclosed, not the actual launch date. Subsequent marketing activity by the same or competing firms is excluded entirely.

For plant heads managing multi-product portfolios, the operational read is straightforward: the list does not confirm whether a given authorized generic remains on the market, nor does it capture the date marketing ceased. FDA acknowledges it frequently lacks that information. Any supply-chain or capacity planning exercise that treats this listing as a real-time market signal should be recalibrated against primary NDA holder data or direct agency correspondence.

The agency is accepting corrections and additions, but with a firm constraint, the list may only reflect information contained in a submitted annual report. Suggested changes, accompanied by supporting documentation, can be directed to AuthorizedGenerics@FDA.HHS.GOV. That channel is the appropriate route for sponsors who identify omissions or inaccuracies affecting their products' market-entry records.

For regulatory affairs leads, the listing's methodology also has implications for 180-day exclusivity analysis and first-to-file strategy: if an authorized generic's market-entry date is misrepresented by a reporting-period approximation, competitive timing assumptions built on that data may be structurally unsound.

The full listing is available as a PDF download from FDA's CDER page and will be updated as corrected annual report data is received.

Source: FDA / CDER via FDA.gov What's New: Drugs RSS Feed, July 2, 2026.